Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mFOLFOX6
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
mFOLFOX6 is a combination chemotherapy regimen primarily used to treat colorectal cancer and other gastrointestinal cancers. The regimen consists of three drugs: leucovorin calcium (folinic acid), fluorouracil (5-FU), and oxaliplatin. These agents work together to destroy rapidly dividing cells, such as cancer cells, by interfering with DNA synthesis and function. Leucovorin enhances the effectiveness of fluorouracil, while oxaliplatin is a platinum-based agent that causes DNA crosslinking and cell death. mFOLFOX6 is administered intravenously in cycles, typically every two weeks[1][2][3][4][5]. It is considered standard care for adjuvant treatment in colorectal cancer and may also be used in combination with other agents for advanced or metastatic disease.
- Brand names
- Eloxatin
- Other names
- modified FOLFOX-6folinic acid + fluorouracil + oxaliplatin
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mFOLFOX6.